{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:40:20Z","timestamp":1792460420170,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-05181-0","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:53:43Z","timestamp":1784868823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efgartigimod-responsive autoimmune peripheral neuropathy with concurrent anti-GM2 IgG and anti-contactin-1 IgG antibodies: a rare case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Ju","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"5181_CR1","doi-asserted-by":"publisher","unstructured":"Shastri A, Al Aiyan A, Kishore U, Farrugia ME. Immune-mediated neuropathies: pathophysiology and management. Int J Mol Sci Apr. 2023;14(8). https:\/\/doi.org\/10.3390\/ijms24087288.","DOI":"10.3390\/ijms24087288"},{"issue":"10","key":"5181_CR2","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.clinph.2013.03.025","volume":"124","author":"A Uncini","year":"2013","unstructured":"Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol Oct. 2013;124(10):1928\u201334. https:\/\/doi.org\/10.1016\/j.clinph.2013.03.025.","journal-title":"Clin Neurophysiol Oct"},{"issue":"11","key":"5181_CR3","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/jnnp-2014-310097","volume":"86","author":"A Uncini","year":"2015","unstructured":"Uncini A, Kuwabara S. Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatry Nov. 2015;86(11):1186\u201395. https:\/\/doi.org\/10.1136\/jnnp-2014-310097.","journal-title":"J Neurol Neurosurg Psychiatry Nov"},{"key":"5181_CR4","doi-asserted-by":"publisher","unstructured":"Quinot V, Rostasy K, H\u00f6ftberger R. Antibody-mediated nodo- and paranodopathies. J Clin Med Sep. 2024;25(19). https:\/\/doi.org\/10.3390\/jcm13195721.","DOI":"10.3390\/jcm13195721"},{"issue":"Pt 6","key":"5181_CR5","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/brain\/awv054","volume":"138","author":"Y Miura","year":"2015","unstructured":"Miura Y, Devaux JJ, Fukami Y, et al. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain Jun. 2015;138(Pt 6):1484\u201391. https:\/\/doi.org\/10.1093\/brain\/awv054.","journal-title":"Brain Jun"},{"key":"5181_CR6","doi-asserted-by":"publisher","unstructured":"Dalakas MC. IgG4-mediated neurologic autoimmunities: understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies. Neurol Neuroimmunol Neuroinflamm Jan. 2022;9(1). https:\/\/doi.org\/10.1212\/nxi.0000000000001116.","DOI":"10.1212\/nxi.0000000000001116"},{"issue":"3","key":"5181_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3988\/jcn.2018.14.3.401","volume":"14","author":"JK Kim","year":"2018","unstructured":"Kim JK, Kim YH, Yoon BA, et al. Clinical heterogeneity of anti-GM2-ganglioside-antibody syndrome. J Clin Neurol Jul. 2018;14(3):401\u20136. https:\/\/doi.org\/10.3988\/jcn.2018.14.3.401.","journal-title":"J Clin Neurol Jul"},{"key":"5181_CR8","doi-asserted-by":"publisher","first-page":"760889","DOI":"10.3389\/fneur.2021.760889","volume":"12","author":"J Zhu","year":"2021","unstructured":"Zhu J, Zhang Y, Li R, et al. Anti-ganglioside antibodies in Guillain-Barre syndrome: a novel immunoblotting-panel assay. Front Neurol. 2021;12:760889. https:\/\/doi.org\/10.3389\/fneur.2021.760889.","journal-title":"Front Neurol"},{"issue":"1\u20132","key":"5181_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/s0165-5728(00)00461-6","volume":"1","author":"B Cavanna","year":"2001","unstructured":"Cavanna B, Jiang H, Allaria S, Carpo M, Scarlato G, Nobile-Orazio E. Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies. J Neuroimmunol Mar. 2001;1(1\u20132):226\u201331. https:\/\/doi.org\/10.1016\/s0165-5728(00)00461-6.","journal-title":"J Neuroimmunol Mar"},{"issue":"3","key":"5181_CR10","doi-asserted-by":"publisher","first-page":"e0281156","DOI":"10.1371\/journal.pone.0281156","volume":"18","author":"J Fehmi","year":"2023","unstructured":"Fehmi J, Davies AJ, Antonelou M, et al. Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis. PLoS ONE. 2023;18(3):e0281156. https:\/\/doi.org\/10.1371\/journal.pone.0281156.","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"5181_CR11","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1007\/s10875-010-9407-4","volume":"30","author":"PA van Doorn","year":"2010","unstructured":"van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain-Barr\u00e9 syndrome. J Clin Immunol May. 2010;30(Suppl 1):S74\u20138. https:\/\/doi.org\/10.1007\/s10875-010-9407-4.","journal-title":"J Clin Immunol May"},{"issue":"3","key":"5181_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ana.23794","volume":"73","author":"L Querol","year":"2013","unstructured":"Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol Mar. 2013;73(3):370\u201380. https:\/\/doi.org\/10.1002\/ana.23794.","journal-title":"Ann Neurol Mar"},{"issue":"5","key":"5181_CR13","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/nxi.0000000000000149","volume":"2","author":"L Querol","year":"2015","unstructured":"Querol L, Rojas-Garc\u00eda R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm Oct. 2015;2(5):e149. https:\/\/doi.org\/10.1212\/nxi.0000000000000149.","journal-title":"Neurol Neuroimmunol Neuroinflamm Oct"},{"issue":"12","key":"5181_CR14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/s1474-4422(13)70215-1","volume":"12","author":"S Kuwabara","year":"2013","unstructured":"Kuwabara S, Yuki N. Axonal Guillain-Barr\u00e9 syndrome: concepts and controversies. Lancet Neurol Dec. 2013;12(12):1180\u20138. https:\/\/doi.org\/10.1016\/s1474-4422(13)70215-1.","journal-title":"Lancet Neurol Dec"},{"issue":"Pt 12","key":"5181_CR15","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/brain\/awf272","volume":"125","author":"HJ Willison","year":"2002","unstructured":"Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain Dec. 2002;125(Pt 12):2591\u2013625. https:\/\/doi.org\/10.1093\/brain\/awf272.","journal-title":"Brain Dec"},{"issue":"Suppl 1","key":"5181_CR16","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1007\/s10875-012-9768-y","volume":"33","author":"T Rath","year":"2013","unstructured":"Rath T, Kuo TT, Baker K, et al. The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol Jan. 2013;33(Suppl 1):S9\u201317. https:\/\/doi.org\/10.1007\/s10875-012-9768-y.","journal-title":"J Clin Immunol Jan"},{"issue":"7","key":"5181_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr., Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol Jul. 2021;20(7):526\u201336. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9.","journal-title":"Lancet Neurol Jul"},{"issue":"3","key":"5181_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrneurol.2014.260","volume":"11","author":"P Stathopoulos","year":"2015","unstructured":"Stathopoulos P, Alexopoulos H, Dalakas MC. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat Rev Neurol Mar. 2015;11(3):143\u201356. https:\/\/doi.org\/10.1038\/nrneurol.2014.260.","journal-title":"Nat Rev Neurol Mar"},{"issue":"5","key":"5181_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/mus.26804","volume":"61","author":"SA Muley","year":"2020","unstructured":"Muley SA, Jacobsen B, Parry G, et al. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve May. 2020;61(5):575\u20139. https:\/\/doi.org\/10.1002\/mus.26804.","journal-title":"Muscle Nerve May"},{"issue":"23","key":"5181_CR20","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/wnl.0000000000007600","volume":"4","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr., Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology Jun. 2019;4(23):e2661\u201373. https:\/\/doi.org\/10.1212\/wnl.0000000000007600.","journal-title":"Neurology Jun"},{"issue":"9","key":"5181_CR21","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1007\/s00415-018-8948-y","volume":"265","author":"GGA van Lieverloo","year":"2018","unstructured":"van Lieverloo GGA, Peric S, Doneddu PE, et al. Corticosteroids in chronic inflammatory demyelinating polyneuropathy: a retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol Sep. 2018;265(9):2052\u20139. https:\/\/doi.org\/10.1007\/s00415-018-8948-y.","journal-title":"J Neurol Sep"},{"issue":"7","key":"5181_CR22","doi-asserted-by":"publisher","first-page":"e70269","DOI":"10.1111\/ene.70269","volume":"32","author":"H Tai","year":"2025","unstructured":"Tai H, Niu S, Pan H, et al. Preliminary observations on the efficacy of efgartigimod therapy in autoimmune nodopathy. Eur J Neurol Jul. 2025;32(7):e70269. https:\/\/doi.org\/10.1111\/ene.70269.","journal-title":"Eur J Neurol Jul"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05181-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05181-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05181-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:08:23Z","timestamp":1792458503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05181-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5181"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05181-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of this case report and any accompanying images was obtained from the patient\u2019s legally authorized representative, as the patient lacked the capacity to provide written consent due to persistent neurological impairment. A copy of the written consent is available for review by the Editor upon reasonable request.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"657"}}